What Vertex Pharmaceuticals Incorporated's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 93 |
| Total trades | 4 | 191 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 14,477 | 432,186 |
| Disposed | 6,000 | 458,290 |
| Net activity | +8,477 | −26,104 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Brennan Daniel J. | Director | Oct 20 | Grant / award · A | +795 | $503.47 | +$400K | 795 |
| van Grunsven Jasper | EVP, CP and NPPO | Sep 08 | Grant / award · A | +8,682 | — | — | 8,682 |
| Ambrose Kristen | SVP & Chief Accounting Officer | Aug 28 | Grant / award · A | +5,000 | — | — | 11,624 |
| Sachs Bruce I | Director | Aug 27 | Gift · G | −6,000 | — | — | 39,000 |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Jul 21 | Grant / award · A | +8,251 | — | — | 53,572 |
| Sachdev Amit | EVP Chief Patient & Ext Af Off | Jul 21 | Grant / award · A | +8,251 | — | — | 66,512 |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Jul 02 | Open-market sale · S | −1,500 | $524.99 | −$787K | 45,321 |
| McKechnie Duncan | EVP, Chief Commercial Officer | Jul 02 | Open-market sale · S | −1,541 | $519.00 | −$800K | 11,001 |
| Liu Joy | EVP and Chief Legal Officer | Jul 01 | Open-market sale · S | −828 | $502.71 | −$416K | 19,131 |
| Bozic Carmen | EVP and CMO | Jun 26 | Open-market sale · S | −596 | $482.50 | −$288K | 15,337 |
| Bozic Carmen | EVP and CMO | Jun 18 | Open-market sale · S | −1,020 | $462.17 | −$471K | 15,933 |
| Bozic Carmen | EVP and CMO | Jun 15 | Open-market sale · S | −4,062 | $450.00 | −$1.83M | 16,953 |
| Bozic Carmen | EVP and CMO | Jun 05 | Open-market sale · S | −1,745 | $450.00 | −$785K | 21,015 |
| Liu Joy | EVP and Chief Legal Officer | Jun 01 | Open-market sale · S | −828 | $439.91 | −$364K | 19,959 |
| Bozic Carmen | EVP and CMO | May 29 | Open-market sale · S | −1,974 | $450.00 | −$888K | 22,760 |
| Bozic Carmen | EVP and CMO | May 15 | Open-market sale · S | −1,354 | $453.45 | −$614K | 24,734 |
| Bunnage Mark E. | EVP, Chief Scientific Officer | May 15 | Open-market sale · S | −33 | $453.45 | −$15K | 7,284 |
| Bozic Carmen | EVP and CMO | May 12 | Open-market sale · S | −6,988 | $450.00 | −$3.14M | 26,088 |
| Bhatia Sangeeta N. | Director | May 04 | Open-market sale · S | −318 | $423.73 | −$135K | 4,924 |
| Schneider Jennifer | Director | May 01 | Disposition to Issuer · D | −796 | — | — | 1,394 |
Loading...
